Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.57 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8303156 | 0.93 | MMP12 (0.57) | MMP12PDE3BPDE3ATP53THRB | |
| SCHEMBL2953764 | 0.86 | MMP12 (0.64) | MMP12PDE3BPDE3ATP53THRB | |
| SCHEMBL3342717 | 0.83 | MMP12 (0.49) | MMP12PDE3BPDE3ATP53THRB | |
| SCHEMBL305188 | 0.83 | MMP12 (0.57) | MMP12PDE3BPDE3ATP53THRB | |
| SCHEMBL3344322 | 0.81 | PARP1 (0.57) | MMP12TP53THRBMAPTALDH1A1 | |
| SCHEMBL30638088 | 0.80 | MMP12 (0.49) | MMP12TP53THRBMAPTALDH1A1 | |
| SCHEMBL7868455 | 0.80 | MMP12 (0.49) | MMP12TP53THRBMAPTALDH1A1 | |
| SCHEMBL1853066 | 0.80 | MMP12 (0.57) | MMP12PDE3BPDE3ATP53THRB | |
| SCHEMBL8303159 | 0.80 | MMP12 (0.49) | MMP12PDE3BPDE3ATP53THRB | |
| SCHEMBL13652221 | 0.78 | MMP12 (0.54) | MMP12PDE3BPDE3ATP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372865-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-02-12 | — | — | US | claimed |
| US-8372865-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-02-12 | — | — | US | disclosed |
| US-20100160373-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
| EP-0548254-B1 | 6- OR 7-(IMIDAZOLIDIN-2-YLIDENEAMINO)-1,4-BENZOXAZINES AS ALPHA ADRENERGIC AGENTS | ALLERGAN INC (US) | 1999-06-02 | — | — | EP | disclosed |
| EP-0548254-A1 | 6- or 7- (2-IMINO-2-IMIDAZOLIDINE)-1,4-BENZOXAZINES AS ALPHA ADRENERGIC AGENTS | ALLERGAN, INC. (US) | 1993-06-30 | — | — | EP | disclosed |
| WO-1992004345-A1 | 6- or 7- (2-IMINO-2-IMIDAZOLIDINE)-1,4-BENZOXAZINES AS ALPHA ADRENERGIC AGENTS | ALLERGAN, INC. (US) | 1992-03-19 | — | — | WO | disclosed |
| US-5091528-A | Antiglaucoma, antidiarrhea agents, diuretics, vasoconstrictors | ALLERGAN, INC. (US) | 1992-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160373-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | P2RY1, P2RX3, P2RX1 | MMP12 3146/4885PDE3B 1272/4885PDE3A 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.